What is the current stock price of Atossa Therapeutics, Inc. (ATOS)?

As of the latest market data, Atossa Therapeutics, Inc. (ATOS) is trading at $4.94. The stock has seen a loss of -0.80% today.

Does Atossa Therapeutics, Inc. (ATOS) pay a dividend?

Based on current data, Atossa Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Atossa Therapeutics, Inc.?

The current market capitalization of Atossa Therapeutics, Inc. (ATOS) is approximately unavailable.

ATOS

Atossa Therapeutics, Inc.·Healthcare

4.94

0.803%(−0.04)

Market Closed

5.48

10.931%(+0.54)

After Hours

Last Updated: — ET

52W L: $3.7652W H: $19.35

ATOS NEWS

prnewswire.com

Mar 25

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth quarter and year ended December 31, 2025 and provides an update on recent corporate developments. "While we have consistently made meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology over the last 12 months, we continue to explore the best opportunities to leverage the technology where it may help to address serious health conditions and unmet medical needs.

defenseworld.net

Mar 22

Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) Critical Comparison

Hyperfine (NASDAQ: HYPR - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk. Analyst Recommendations This is a summary of current

globenewswire.com

Mar 19

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science.

prnewswire.com

Mar 19

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.

prnewswire.com

Mar 12

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL. Presentation Highlights The mdx5Cv Dystrophic mouse model, a trusted, reproducible standard for Duchenne muscular dystrophy (DMD) preclinical research, was used for this study (Z)-Endoxifen improved muscle strength and motor performance in both juvenile and adult dystrophic mice Treatment enhanced resistance to contraction-induced muscle injury Favorable changes were observed in body composition, including increased lean mass and reduced fat mass Key biochemical and histologic markers of muscle damage were reduced The therapy was well tolerated with no adverse findings observed during the study Clinical Significance DMD is a progressive and ultimately fatal neuromuscular disorder characterized by ongoing muscle degeneration, inflammation, and fibrosis.

defenseworld.net

Feb 20

Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts

Shares of Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) have earned a consensus recommendation of "Hold" from the five research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2012-11-08

Beta

1.34

Websitewww.atossatherapeutics.com↗